These data suggest that heterogeneity in the expression of oncogenic EGFR mutations may contribute to therapy resistance and combining multiple EGFR inhibitors that act through different mechanisms may be required in glioblastoma patients who carry multiple EGFR variants. Here, EGFR is linked to glioblastoma.